Click here to see the latest financial spreadsheet.
Review of Activities, Achievements and Future Plans 2025.
Our research work at City, St George’s University of London, continued steadily during the year. The focus has been on identifying novel therapeutics that can potentially target pancreatic cancer cells. Several combination treatments have been investigated to ascertain how the combination of drugs affect pancreatic cell movement, viability and survival. This is particularly important when the process of metastasis is considered, which occurs when cancerous cells move from their primary site and spread to other organs and tissues.
The research team feel they are making real strides in delving into ways to fight pancreatic cancer. It’s difficult to expand further about the results as they are commercially sensitive and defined established protocols have to be followed prior to publication.
Donations were significantly down on the prior year due to our having participated last year in an appeal in the memory of a Richard Nevill, who unfortunately died of pancreatic cancer during the appeal. The research team which the appeal is funding, is now based at the University of Birmingham. Our involvement in the appeal has now ceased.
However, the receipt of donations currently remains lower than we would like and this could probably be said about many small charities. The Trustees are actively involved in fundraising and are exploring all avenues to ensure the Fund can meet its aim of finding a cure for a terrible illness.
In August 2024, the business and assets of St George’s were merged with City, University of London. St George’s is now known as “City, St George’s University of London”. The merger has had no effect on our Charity.
On 1 August 2024, the business and assets of St George’s will transfer to City, University of London, under a merger Agreement between the two organisations. The merged businesses will be renamed “City St George’s, University of London”. The Trustees do not feel this merger will have any effect on our research.
FINANCIAL REVIEW
During the year donations and other income amounted to £90,516 (2023 – £70,435) and expenditure was £215,997 (2023 – £5,463) leaving an excess of Expenditure over Income of £125,480 (2023 – surplus of +£64,972), which is transferred to the Unrestricted Funds brought forward which stand at minus -£24,757 and Restricted £498, totaling minus -£24,259 (2023- +£101,221).
See previous financial reports:
